Bicara Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Bicara Therapeutics Inc. (BCAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.07 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 681.47K shares, a 11.40% increase year-over-year.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.39M shares, a 643.25% increase year-over-year.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 1.21M shares, a 952.72% increase year-over-year.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 416.00K shares.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.56M shares, a 32.06% decline from fiscal 2024.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.77M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 681.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 3.07M shares 10-Q · filed 2026-08-11 | 4.28M shares derived: sum of 3 quarters · filed 2026-08-11 | 4.70M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 2.39M shares 10-Q · filed 2026-05-11 | 3.60M shares derived: sum of 2 quarters · filed 2026-05-11 | 4.02M shares derived: sum of 3 quarters · filed 2026-05-11 | 4.63M shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 1.21M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 1.63M shares derived: sum of 2 quarters · filed 2026-03-30 | 2.24M shares derived: sum of 3 quarters · filed 2026-03-30 | 2.56M shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 416.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 1.03M shares derived: sum of 2 quarters · filed 2025-11-10 | 1.35M shares 10-Q · filed 2025-11-10 | 1.46M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 611.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 933.22K shares 10-Q · filed 2025-08-12 | 1.05M shares derived: sum of 3 quarters · filed 2025-08-12 | |
| 2025-03-31 | 321.50K shares 10-Q · filed 2025-05-13 | 436.50K shares derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2024-12-31 | 115.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 3.77M shares 10-K · filed 2025-03-27 | ||
| 2024-09-30 | 3.65M shares 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |